Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders

Figure 4

⁶⁸Ga-BPAMD was injected i.v. into a patient with known extensive bone metastases of prostate cancer. ⁶⁸Ga-BPAMD (maximum intensity projection (MIP) 50 min after injection (p.i.), 462 MBq) revealed intense accumulation in multiple osteoblastic lesions in the central skeleton, ribs, and proximal extremities: (a) = coronal PET, (b) = sagittal PET/CT. For comparison, (c) shows ¹⁸F-fluoride PET (sagittal, MIP 90 min p.i., 270 MBq). With kind permission from Springer Science + Business Media: [36].

(a)

(b)

(c)